Raymond Tabibiazar (Aravive Biologics Inc)

Targeting GAS6 in cancer, fibrosis and viral infection

9 March 2017 | By Amato J Giaccia (Stanford University), Raymond Tabibiazar (Aravive Biologics Inc), Rebecca Miao (Stanford University)

The growth-arrest specific 6 (GAS6) protein has emerged in recent years as an attractive target for drug development primarily because it is the sole ligand for the AXL receptor tyrosine kinase, which plays critical roles in cancer, fibrosis, and viral infection.